Preventing and Responding to HIV Drug Resistance in the African Region: Regional action plan 2019-2023

Report cover with image of virus

World Health Organisation

Global action to combat HIV/AIDS has had an immense impact in the African Region. By the end of 2017, 15.3 million people living with HIV (PLHIV) in the African Region were accessing life-saving antiretroviral drugs (ARVs), representing 70% of the 21.7 million people accessing antiretrovirals (ARV) globally.

WHO and the Joint United Nations Programme on HIV/ AIDS (UNAIDS) have set the target of 90% of people living with HIV on antiretroviral therapy (ART) achieving virological suppression by 2020. However, the potential positive impact from the scale-up of ART is under threat from an increase in the prevalence of HIV drug resistance (HIVDR). As the prevalence of HIVDR in the African Region increases, the impact on society, the economy and on health could be severe (2,3). If the prevalence of pretreatment HIV drug resistance (PDR) to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in sub-Saharan Africa exceeds 10% and NNRTIs continue to be used in first-line ART regimens, over a five-year period, NNRTI PDR may be responsible for a cumulative 135 000 AIDS-related deaths, 105 000 new HIV infections and an additional US$ 650 million will be spent on ARVs in sub-Saharan Africa.

September 21, 2020
Year of publication
Resource types
Booklets, Reports and Fact sheets
Africa, HIV drug resistance (HIVDR)

Similar Resources

The latest global results highlight PEPFAR-supported activities across the countries in which the organization works.

Timely access to antiretroviral treatment (ART) is vital to ensuring safe motherhood and reducing vertical transmission. Treatment guidance and programming has changed dramatically in recent years.

The COVID-19 pandemic has exposed the inadequacy of investments in public health, the persistence of profound economic and social inequalities and the fragility of many key global systems and approaches.

Recent developments in health practices that were once in the full control of healthcare professionals and can now be safely self-administered have created a shift in thinking about how individuals engage in self-care.

The International AIDS Conference (IAC) is by far the largest conference on HIV related issues. This prestigious conference is the premier gathering for those working in the field of HIV, as well as policy makers, people living with HIV and others committed to ending the epidemic.

AVERT's searchable hub is a comprehensive collection of all its HIV and AIDS-related infographics, videos, audio and photo galleries.

To understand the uptake of HIV services by adolescent women, the authors conducted a retrospective analysis of patient-level data (2011–2013) on services for antenatal care (ANC) and prevention of mother-to-child transmission (PMTCT) in 36 facilities in 5 districts in Zimbabwe.

Remarkable progress is being made on HIV treatment. Ahead of World AIDS Day, UNAIDS has launched a new report showing that access to treatment has risen significantly. In 2000, just 685 000 people living with HIV had access to antiretroviral therapy.

In our first issue, we have assembled 161 abstracts published from December 2017 through January 2018 that feature articles from Botswana (8), Lesotho (1), Malawi (19), Mozambique (9), Namibia (3), South Africa (82), Swaziland (10), Tanzania (2), Zambia (18) and Zimbabwe (19).
In our second issue, we have assembled 84 abstracts published from February through March 2018 that feature articles from Botswana (4), DRC (1), Lesotho (5), Malawi (16), South Africa (39), Swaziland (5), Zambia (5) and Zimbabwe (9).